Ther4

About Theripion

Theripion is a preclinical-stage biotechnology company founded in 2018 and based in Cambridge, USA, with a stated secondary location in Seattle. The company has developed a proprietary Paraoxonase Fusion Protein Platform to create bifunctional therapeutics aimed at diseases involving oxidative stress, inflammation, and dysfunctional lipid metabolism. With a leadership team possessing decades of combined industry experience, Theripion is seeking partnerships and funding to advance its lead candidates, including TR-43 and Ther4, into clinical trials. The company's core value proposition is rescuing patients from conditions like cardiovascular disease, rheumatoid arthritis, and neurodegenerative disorders.

Therapeutic Areas